Published in J Exp Med on July 01, 1987
Cytokines in asthma. Thorax (1999) 2.64
The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J Exp Med (1993) 2.50
Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest (1988) 2.15
Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood (2012) 2.08
Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest (1999) 2.05
Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med (1989) 1.97
Sorting out the cytokines of asthma. J Exp Med (1996) 1.92
T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med (1999) 1.90
Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice. J Clin Invest (1997) 1.86
Mature human eosinophils have the capacity to express HLA-DR. Proc Natl Acad Sci U S A (1989) 1.62
CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration. J Exp Med (1991) 1.58
Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol (2013) 1.47
Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet (1998) 1.33
Nerve growth factor promotes human hemopoietic colony growth and differentiation. Proc Natl Acad Sci U S A (1988) 1.28
Adhesion to fibronectin prolongs eosinophil survival. J Exp Med (1993) 1.25
Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol (1991) 1.19
Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120. J Exp Med (1989) 1.16
Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization. J Clin Invest (1991) 1.16
Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium. J Clin Invest (1991) 1.16
A Schistosoma mansoni epitope recognized by a protective monoclonal antibody is identical to the stage-specific embryonic antigen 1. Proc Natl Acad Sci U S A (1990) 1.16
Production of granulocyte-macrophage colony-stimulating factor by cultured human tracheal epithelial cells. Immunology (1992) 1.14
Cytokines. 3. Cytokines in asthma. Thorax (1993) 1.12
Eosinophils in the 1990s: new perspectives on their role in health and disease. Postgrad Med J (1994) 1.11
Cytokine/anti-cytokine therapy - novel treatments for asthma? Br J Pharmacol (2011) 1.11
Shape changes, exocytosis, and cytosolic free calcium changes in stimulated human eosinophils. J Clin Invest (1991) 1.10
Cysteinyl leukotrienes and their receptors; emerging concepts. Allergy Asthma Immunol Res (2014) 1.10
CD40 expression by human peripheral blood eosinophils. J Clin Invest (1996) 1.07
Compartmentalized transgene expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) in mouse lung enhances allergic airways inflammation. Clin Exp Immunol (1998) 1.04
Human fibroblasts maintain the viability and augment the functional response of human neutrophils in culture. J Clin Invest (1990) 0.96
The effects of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 on the secretory capacity of human blood eosinophils. Clin Exp Immunol (1990) 0.94
Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome. Proc Natl Acad Sci U S A (1990) 0.93
Human eosinophils stimulate DNA synthesis and matrix production in dermal fibroblasts. Arch Dermatol Res (1994) 0.91
Cellular responses to human chondrocytes: absence of allogeneic responses in the presence of HLA-DR and ICAM-1. Clin Exp Immunol (1992) 0.89
Gene expression of interleukin-2 in purified human peripheral blood eosinophils. Immunology (1996) 0.88
A morphometric study of normodense and hypodense human eosinophils that are derived in vivo and in vitro. Am J Pathol (1990) 0.86
Glucocorticoids inhibit granulocyte-macrophage colony-stimulating factor-1 and interleukin-5 enhanced in vitro survival of human eosinophils. Immunology (1992) 0.85
Interleukin-3-induced up-regulation of CR3 expression on human eosinophils is inhibited by dexamethasone. Immunology (1992) 0.84
Lymphocytes stimulate expression of 5-lipoxygenase and its activating protein in monocytes in vitro via granulocyte macrophage colony-stimulating factor and interleukin 3. J Clin Invest (1996) 0.82
Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice. Br J Pharmacol (1993) 0.82
Eosinophils altered phenotypically and primed by culture with granulocyte/macrophage colony-stimulating factor and 3T3 fibroblasts generate leukotriene C4 in response to FMLP. J Clin Invest (1991) 0.82
Pretreatment with rh-GMCSF, but not rh-IL3, enhances PAF-induced eosinophil accumulation in guinea-pig airways. Br J Pharmacol (1990) 0.82
Excretory-secretory product of newly excysted metacercariae of Paragonimus westermani directly induces eosinophil apoptosis. Korean J Parasitol (2000) 0.82
Positive interaction of the beta2-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guinea-pigs. Br J Pharmacol (2005) 0.80
Characteristics of an anti-eosinophil monoclonal antibody that recognizes granulocytes from patients with blood eosinophilia but not from subjects without eosinophilia. Clin Exp Immunol (1991) 0.79
The potential role of recombinant hematopoietic colony-stimulating factors in preventing infections in the immunocompromised host. Can J Infect Dis (1991) 0.78
Psychological stress and aging: role of glucocorticoids (GCs). Age (Dordr) (2011) 0.78
Effects of two types of inactivity on the number of white blood cells in rats. Eur J Appl Physiol (2006) 0.78
Alteration in the density, morphology, and biological properties of eosinophils produced by bullous pemphigoid blister fluid. Arch Dermatol Res (1989) 0.77
Regulation of nasal airway homeostasis and inflammation in mice by SHP-1 and Th2/Th1 signaling pathways. PLoS One (2014) 0.77
Characterization of platelet-activating factor synthesized by normal and granulocyte-macrophage colony-stimulating factor-primed human eosinophils. Immunology (1992) 0.77
A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer. Br J Cancer (1994) 0.77
Altered esophageal histamine receptor expression in Eosinophilic Esophagitis (EoE): implications on disease pathogenesis. PLoS One (2015) 0.76
Group 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production. J Immunol (2015) 0.76
Density heterogeneity of eosinophil leucocytes: induction of hypodense eosinophils by platelet-activating factor. Immunology (1989) 0.76
Anti-inflammatory agents in allergic diseases. Clin Exp Immunol (1995) 0.75
Constitutive production of granulocyte/macrophage colony-stimulating factor by hypodense mononuclear eosinophils developed in vitro from hybrid eosinophil/basophil granulocytes. Proc Natl Acad Sci U S A (1996) 0.75
Effects of Asian Dust Particles on the Early-Stage Antigen-Induced Immune Response of Asthma in NC/Nga Mice. Int J Environ Res Public Health (2016) 0.75
Protective effects of cyclophosphamide, cyclosporin A and FK506 against antigen-induced lung eosinophilia in guinea-pigs. Clin Exp Immunol (1992) 0.75
Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science (1985) 8.72
Mechanism of eosinophilia. II. Role of the lymphocyte. J Exp Med (1970) 4.34
A new method for the purification of human eosinophils and neutrophils, and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni. J Immunol (1979) 4.17
Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. Science (1984) 3.84
Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest (1986) 3.78
Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med (1968) 3.28
Hyperinfection syndrome with Strongyloides stercoralis. Ann Intern Med (1970) 2.47
Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood (1986) 2.45
Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature (1986) 2.36
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
Heterogeneity of human peripheral blood eosinophils: variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. Int Arch Allergy Appl Immunol (1983) 2.17
Total eosinophil counts in the management of bronchial asthma. N Engl J Med (1975) 2.09
Coculture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc Natl Acad Sci U S A (1986) 2.00
High-affinity binding of granulocyte-macrophage colony-stimulating factor to normal and leukemic human myeloid cells. Proc Natl Acad Sci U S A (1986) 1.76
Schistosomiasis in the congenitally athymic (nude) mouse. I. Thymic dependency of eosinophilia, granuloma formation, and host morbidity. J Immunol (1977) 1.68
Mechanisms for eosinophilic and neutrophilic leucocytoses. Br Med J (1971) 1.66
Cell-mediated damage to helminths. Adv Parasitol (1984) 1.64
Fibroblasts maintain the phenotype and viability of the rat heparin-containing mast cell in vitro. J Immunol (1985) 1.52
Synthesis and release of leukotriene C4 by human eosinophils. J Immunol (1987) 1.47
Mechanism of eosinophilia. V. Kinetics of normal and accelerated eosinopoiesis. Cell Tissue Kinet (1971) 1.42
Release of leukotriene C4 from human eosinophils and its relation to the cell density. Int Arch Allergy Appl Immunol (1985) 1.20
A high-efficiency cloning system for single hapten-specific B lymphocytes that is suitable for assay of putative growth and differentiation factors. Proc Natl Acad Sci U S A (1985) 1.11
Hematologic manifestations of parasitic infections. Semin Hematol (1971) 1.08
Maturation in vivo of Schistosoma mansoni schistosomula after culture in vitro with granulocytes and antibody. Infect Immun (1983) 0.97
Eosinophilopoietin production: relationship to eosinophilia of infection and thymus function. Trans Assoc Am Physicians (1979) 0.88
Cold urticaria: release into the circulation of histamine and eosinophil chemotactic factor of anaphylaxis during cold challenge. N Engl J Med (1976) 17.77
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol (1971) 5.41
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol (1969) 4.38
A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med (1971) 4.07
Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med (1990) 4.06
Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med (1985) 4.00
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. Science (1984) 3.84
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
A neutrophil-immobilizing factor derived from human leukocytes. I. Generation and partial characterization. J Exp Med (1972) 3.75
Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature (1985) 3.73
The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung. J Immunol (1971) 3.51
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest (2001) 3.32
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. J Exp Med (1972) 3.31
Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A (1983) 3.30
The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest (1984) 3.26
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol (1968) 3.24
Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science (1988) 3.22
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component. J Immunol (1967) 3.18
Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol (1983) 3.18
Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A (1980) 3.18
Postnatal mammary gland development requires macrophages and eosinophils. Development (2000) 3.10
The complement system of man. I. N Engl J Med (1972) 3.09
Antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-A) in the guinea pig and rat. J Exp Med (1967) 3.08
A pre-albumin activator of prekallikrein. J Immunol (1970) 2.95
Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A (1980) 2.94
Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J Clin Invest (1974) 2.90
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol (1984) 2.85
Native heparin from rat peritoneal mast cells. J Biol Chem (1977) 2.79
Inactivation of slow reacting substance of anaphylaxis by human eosinophil arylsulfatase. J Immunol (1975) 2.73
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol (1982) 2.69
An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med (1971) 2.65
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis. Proc Natl Acad Sci U S A (1975) 2.56
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. II. Influence of cellular levels of cyclic AMP. Fed Proc (1972) 2.55
Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med (1996) 2.55
The complement system in rheumatoid synovitis. I. An analysis of complement component activities in rheumatoid synovial fluids. Arthritis Rheum (1971) 2.53
Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun (1980) 2.49
Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis (1991) 2.43
Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature (1981) 2.41
Immunological release of histamine and slow-reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3',5'-adenosine monophosphate. J Exp Med (1971) 2.39
Tryptase from human pulmonary mast cells. Purification and characterization. J Biol Chem (1981) 2.37
Molecular characterization of genome of a novel human T-cell leukaemia virus. Nature (1983) 2.36
The physicochemical characteristics and purification of slow-reacting substance of anaphylaxis. J Immunol (1973) 2.34
Heparin is essential for the storage of specific granule proteases in mast cells. Nature (1999) 2.34
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Hereditary deficiency of the second component of complement (C'2) in man. J Clin Invest (1966) 2.32
Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis. Gut (2010) 2.31
The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med (1972) 2.31
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
Tumor-associated eosinophilotactic factor. N Engl J Med (1974) 2.27
Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature (1985) 2.25
Slow reacting substance of anaphylaxis. Adv Immunol (1969) 2.23
Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci U S A (1975) 2.20
Inactivation of slow reacting substance of anaphylaxins (SRS-A) by arylsulfatases. J Immunol (1974) 2.19
Properdin factor D. II. Activation to D by properdin. J Exp Med (1974) 2.19
Hereditary deficiency of the second component of complement (C2) in man: correlation of C2 haemolytic activity with immunochemical measurements of C2 protein. Immunology (1970) 2.17
Effects of intravenous administration of slow-reacting substance of anaphylaxis, histamine, bradykinin, and prostaglandin F2alpha on pulmonary mechanics in the guinea pig. J Clin Invest (1974) 2.16
Cyclic AMP, ATP, and reversed anaphylactic histamine release from rat mast cells. J Immunol (1974) 2.16
Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest (1988) 2.15
Culture from mouse bone marrow of a subclass of mast cells possessing a distinct chondroitin sulfate proteoglycan with glycosaminoglycans rich in N-acetylgalactosamine-4,6-disulfate. J Biol Chem (1982) 2.13
Interaction of plasma kallikrein with the C1 inhibitor. J Immunol (1970) 2.07
Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection. N Engl J Med (1980) 2.07
Leukotriene B4 action on endothelium mediates augmented neutrophil/endothelial adhesion. Proc Natl Acad Sci U S A (1984) 2.06
Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci U S A (2008) 2.06
Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest (1999) 2.05
Immunologic release of beta-hexosaminidase and beta-glucuronidase from purified rat serosal mast cells. J Immunol (1979) 2.01
Coculture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc Natl Acad Sci U S A (1986) 2.00
A beta-glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway. J Immunol (1985) 2.00
Hereditary deficiency of the second component of complement (C'2) in man: further observations on a second kindred. J Immunol (1967) 1.98
Eotaxin is required for the baseline level of tissue eosinophils. Proc Natl Acad Sci U S A (1998) 1.98
Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med (1989) 1.97
Characterization of the human granulocyte-macrophage colony-stimulating factor promoter region by genetic analysis: correlation with DNase I footprinting. Mol Cell Biol (1988) 1.97
Initiation of C3 cleavage in the alternative complement pathway. J Immunol (1975) 1.94
Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae. Proc Natl Acad Sci U S A (1986) 1.93